HCERES report on research unit: Under the supervision of the following institutions and research bodies:

Similar documents
REPORT ON THE CIC: Centre d Investigation Clinique Intégré en Biothérapie (CIC-BT)

2014 ACTIVITY REPORT 2014

A WORLD-CLASS HIGHER EDUCATION AND RESEARCH ESTABLISHMENT

Recruiting emerging leaders in oncology Leaders de demain en oncologie

RESEARCH & INNOVATION

ROP ERDF Abruzzo Action I.1.1 I.1.4 ABRUZZO Region

A university wishing to have an accredited program in adult Infectious Diseases must also sponsor an accredited program in Internal Medicine.

Training Requirements for the Specialty of Medical Microbiology

2018 CALL FOR POST-DOCTORAL APPLICATIONS

5/9/17. Healthcare-Associated Infections Cultural Shift. Background. Disclosures and Disclaimers

Networks and Clusters: initiatives for a knowledge based economy in France

Clinical Microbiology and Infectious Diseases Working together. An ESCMID perspective.

The European Research Council

Organizational Structure Ossama Rasslan

French HORIZON 2020 support system

UNIVERSITÉ DE LORRAINE

Post-Doctoral applications Guidelines

Electronic Health Records for research and Hospital management. The "Assistance Publique - Hôpitaux de Paris" initiative

TRUST BOARD. Date of Meeting: 05/10/2010

Infection Prevention and Control Strategy (NHSCT/11/379)

Infectious Diseases in Clinical Practice:

UNIVERSITIES ROLES IN INNOVATION ECOSYSTEMS PARISTECH (FRANCE)

Telehealth: a strategy to support the practice of physicians in remote areas

Franco-Pakistani Research Collaboration Dr. Riaz Ahmad

MGH ECOR Fellowships for Postdocs: How to Write a Competitive Application

Laboratory Assessment Tool

RUSI/STFC Workshop. Tackling Antimicrobial Resistance: Identifying Future Research Themes. 6 February 2013

Impact the World: Human Health President s Report to the Board of Trustees November 10, 2017

MIMM MOLECULAR MICROBIOLOGY LAB

PRC (Projets de Recherche Conjoints) (Joint Research Projects)

Malawi Outpatient HIV Clinic Curriculum

US ): [42CFR ]:

The European Research Council

Centre National de la Recherche Scientifique CNRS. CNRS and AFRICA. Chamira Lessigny Europe of Research and International Cooperation Office, Derci

Alpha-1 Foundation Letter of Intent and Full Application Instructions

The European Research Council. The ERC Scientific Strategy. Barbara Ensoli. Member of the ERC Scientific Council

Mandatory accreditation of Medical labs in France: Benchmark for the EU countries? Michel Vaubourdolle

Annex for Franco- Mexican Projects Non-Lead Agency Procedure

Clinical Laboratory Technologist

REPOSITIONING OUR CLINICAL LABORATORIES FOR EFFECTIVE AND EFFICIENT HEALTHCARE DELIVERY. By Prof. Ibironke Akinsete Chairman PathCare Nigeria

The European Research Council

Patient Safety Course Descriptions

Medical Research Fellows Program

Manual of Notification of Infectious diseases By DR Mohammad Abou ele la Professor of Medical Microbiology & Immunology,Mansoura Faculty of Medicine

French National Center for Scientific Research

Minimum Criteria for Common Infections Toolkit. [Name] [Organization]

External Publication of Job Posting

Infectious Diseases in Clinical Practice:

Learning Objectives. John T. Mather Memorial Hospital

2016 Edition, third call. Call for proposals closing date. 23 February 2016 at 1 pm (Paris time) Call for proposals publication address

External Publication of Job Posting

For an informal discussion, please contact Geoff Day, Laboratory Manager on or

ERN board of Member States

APPLICATION FOR A CLARE COLLEGE SUMMER PLACEMENT SCHEME

Infectious EUH Learning Activities:

presents OHIO biomedical and pharma career fair April 15 2pm 6pm Columbus, Ohio Exhibitor Booklet

Senior Research, Measurement and Evaluation Officer (based in Abuja) Project: SIFPO/LEAP Project

Infectious Diseases in Clinical Practice:

Mandatory accreditation of medical laboratories in France: how to best reconcile regulatory and normative requirements for cytogenetics?

INFECTIOUS DISEASE MEDICINE FOR PRIMARY CARE

53. MASTER OF SCIENCE PROGRAM IN GENERAL MEDICINE, UNDIVIDED TRAINING PROGRAM. 1. Name of the Master of Science program: general medicine

Acinetobacter nd Announcement. 9th International Symposium on the Biology of Acinetobacter

Medical School Clinical Sciences AHC Strategic Planning Initiative 2000

GUIDE FOR APPLICANT 2015

Alpha-1 Foundation Letter of Intent Application Instructions

Annex for Franco - Taiwanese Projects Non-Lead Agency Procedure


IMPROVEMENT IN PATIENT MANAGEMENT THROUGH THE USE OF A Clostridium difficile PCR REAL TIME STAND ALONE TEST IN ACUTE HOSPITAL SETTING

Returning to Europe after 7 years in the United States and Japan

DISCLOSURE HOSPITAL ACCREDITATION: AIM OR MEANS. No Conflict of interest to declare PAUL VAN OSTENBERG, DDS, MS

Call for Projects 2018

Call for Projects 2018

Annex for Franco-Singaporean Projects Non-Lead Agency Procedure

Prairie North Regional Health Authority: Hospital-acquired infections

Oregon Clinical and Translational Research KL2 Program

Sophie Torloting Regional Council of Lorraine

Alzheimer s Association Clinical Fellowship (AACF) Program

ALS Canada-Brain Canada Discovery Grants

Value Added Medicines Rethink, Reinvent & Optimize Medicines, Improving Patient Health & Access

European Research Council Grants in H2020

Annex for Franco- HK Projects Non-Lead Agency Procedure

African For the purposes of the AREF Research Development Competition 2016, Africa and African refer to the countries of Sub-Saharan Africa.

BIOGRAPHICAL DATA Docteur (Ph.D.) en Sciences Physiques (La Plus Grande Distinction), Université Libre de Bruxelles.

MAKE OUR PLANET GREAT AGAIN

FEMTO-ST SPIE Student Chapter Annual Report Annual Report

Ethical issues arising from the requirement to provide written

Healthcare Acquired Infections

Billing Code: P DEPARTMENT OF HEALTH AND HUMAN SERVICES. Centers for Disease Control and Prevention. [30Day ]

San Francisco General Hospital INFECTION CONTROL

Current trends in European microbiology

Table 1: Indicative budget lines

Pediatric Nursing. Neonatal & Neonatal Nursing Theme: Explore the Advances in Neonatal and Pediatric Nursing. 29 th International Conference on

F31 Sponsors, Collaborators and Institutional Environment

The European Research Council. Art & Build Architect / Montois Partners / credits: S. Brison

Meeting the Challenges of Global Laboratory Systems Development: Human Resources Capacity Development

INFECTIOUS DISEASE MEDICINE FOR PRIMARY CARE. Napa Valley/Sonoma, California The Fairmont Sonoma Mission Inn & Spa October 2 4, 2015

How to Add an Annual Facility Survey

MSCRF Discovery Program

INVITED REVIEW. Richard W. REDMAN INTRODUCTION GLOBAL PERSPECTIVE. Abstract

Transcription:

Research units HCERES report on research unit: Groupe de Recherche sur l'adaptation Microbienne GRAM 2.0 Under the supervision of the following institutions and research bodies: Université de Rouen Université de Caen Basse-Normandie - UCBN Evaluation Campaign 2015-2016 (Group B)

Research units In the name of HCERES, 1 Michel Cosnard, president In the name of the experts committee, 2 David O Callaghan, chairman of the committee Under the decree No.2014-1365 dated 14 november 2014, 1 The president of HCERES "countersigns the evaluation reports set up by the experts committees and signed by their chairman." (Article 8, paragraph 5) 2 The evaluation reports "are signed by the chairman of the expert committee". (Article 11, paragraph 2)

Evaluation report This report is the sole result of evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee. Unit name: Groupe de Recherche sur l'adaptation Microbienne Unit acronym: GRAM 2.0 Label requested: EA Current number: 2656 Name of Director (2015-2016): Name of Project Leader (2017-2021): Mr François CARON Mr François CARON Expert committee members Chair: Mr David O CALLAGHAN, Université de Montpellier Experts: Mr José ENTENZA, Universié de Lausanne, Switzerland Mr Philippe VAN DE PERRE, Université de Montpellier Scientific delegate representing the HCERES: Ms Catherine SCHUSTER Representatives of supervising institutions and bodies: Mr Cafer ÖZKUL, Université de Rouen Mr Laurent YON, Université de Rouen Head of Doctoral School: Mr Patrice LEROUGE, Doctoral School n 497, Normandy's Doctoral School of Integrative Biology, Health and Environment, NBISE. 3

1 Introduction History and geographical location of the unit The Groupe de Recherche sur les Antimicrobiens et les Micro-organismes (GRAM 1.0, EA 2656) was created in 1998 to structure work on infectious diseases at the Medicine and Pharmacy Faculties of the University of Rouen. The group is located in the Rouen Martainville campus, and benefits from both university research laboratories and hospital bacteriology and virology diagnostic laboratories. The group is part of the Institut de Recherche et d'innovation Biomédicale de Haute-Normandie which federates biomedical research in the Region and provides mutualised technological platforms. In the new project, the Rouen group plans to merge with one of the teams of the unit U2RM (EA4655), a team of clinicians and microbiologists from the University Hospital laboratories in Caen to reinforce the strengths in virology, but it also brings together researchers from the team Antibiotic-Resistance (E2) of U2RM and a researcher of a team of Rouen working on respiratory disability (from EA 3613). Management team Since 2011, the laboratory has been directed by Mr François CARON. He will remain as laboratory director with Ms Astrid VABRET and Mr Jean Christophe PLANTIER as deputy directors. HCERES nomenclature SVE1_LS6 Immunology, microbiology, virology, parasitology. Scientific domains The laboratory works on human infectious diseases, in the fields of bacteriology and virology. 4

Unit workforce Unit workforce Number on 30/06/2015 Number on 01/01/2017 N1: Permanent professors and similar positions 7 13 N2: Permanent researchers from Institutions and similar positions 4 4 N3: Other permanent staff (technicians and administrative personnel) 2 1 N4: Other professors (Emeritus Professor, on-contract Professor, etc.) N5: Other researchers from Institutions (Emeritus Research Director, Postdoctoral students, visitors, etc.) N6: Other contractual staff (technicians and administrative personnel) N7: PhD students 8 TOTAL N1 to N7 21 Qualified research supervisors (HDR) or similar positions 4 Unit record From 01/01/2010 to 30/06/2015 PhD theses defended 8 Postdoctoral scientists having spent at least 12 months in the unit Number of Research Supervisor Qualifications (HDR) obtained during the period 1 2 Overall assessment of the unit Introduction The unit works on several aspects of clinical microbiology. In the field of bacteriology, unit members are investigating the dynamics of the bacterial cell wall (Clostridium difficile and Staphylococcus lugdunensis), antibiotic resistance and urinary tract infections. They have been also strongly involved in the control of a local epidemic of meningococcal meningitis. The virologists in the group work on the genetic diversity of HIV and its impact on diagnosis accuracy and anti-retroviral therapy. The laboratory is a Laboratoire Associé of the French national reference centre (CNR-LA) for HIV and is a collaborating laboratory for the CNR Anaérobies providing expertise on C. difficile. The team members and research interests of the unit have been stable since the last evaluation in 2011. The committee noted that the unit has reinforced the virology aspects of the projects, as suggested in the last evaluation report. In the new project, the Rouen group plans to merge with one of the team 3 of the unit U2RM (EA4655), 5

reinforce the strengths in virology, but it also aggregates researchers from the team «Antibiotic-Resistance» (E2) of U2RM and a researcher of a team of Rouen working on respiratory disability (from EA 3613). Global assessment of the unit The performance of GRAM 1.0 is very good. Despite the modest size of the group and the important workloads of clinical duties and teaching, the group is very productive. Over the last 5 years, GRAM 1.0 has published 118 original articles in peer-reviewed journals with a high impact; the unit also shares with the University of Paris Descartes a patent describing a method for the detection and quantification of HIV-2. The unit has demonstrated its ability to obtain funding from public sources and from industry. The national and international visibility of the laboratory is good; unit members have several collaborations with groups in France, Europe, Africa and the USA, including providing rare HIV isolates to FDA and NIH (USA). The director and co-director of the laboratory have participated in the organization of several international conferences (including RICAI and IRIB), and are advisors of national health and regulatory agencies (ANRS, ANSM). The laboratory is very attractive to young scientists, although it still has difficulties in attracting post-doctoral fellows. The planned merger with research teams in Caen is a great opportunity to further increase the laboratory potential. It represents, however, a new challenge since the groups must learn to work together, despite the geographic distance. Strengths and opportunities in the context the lab is very productive, with a good publication record (numbers as well as impact); the lab has original research projects; the lab has good interactions with the Centre Hospitalier Universitaire and various Centre National de Référence (CNR); the lab has access to patients, clinical samples and isolates; the unit has a strong local, national and international network of collaborations and national and international recognition; lab members have a strong implication in teaching, providing visibility and ability to attract students; there is a high level of professional insertion of PhD students after graduation; the planned merger with teams of unit U2RM will increase the critical mass of the unit and the synergy in virology will increase the international competitiveness of the lab; the unit benefits from the strong financial support from the region, for research and infrastructures. Weaknesses and threats in the context the team is built on university hospital clinicians who have a considerable teaching load and numerous responsibilities at the hospital. There are no permanent full-time scientists or full-time post-docs. The laboratory has small technical staff, with only one adjoint technique who has a considerable teaching load (practical courses in microbiology) and, as the laboratory has no secretarial staff, administrative duties; the committee noted a lack of clear scientific focus for such a small group: there are too many research themes; while the merger with researchers from U2RM (EA4655) of Caen will increase the potential of the unit, it is a double-edged sword; there must be a clear planning of how such geographically distant groups will work together as a single unit. It also increases the diversity of research themes. Recommendations The unit has been very successful so far. the unit should define its ambitions for the middle term future (from 2022); do they wish to stay as an EA, or are they tempted to apply for an INSERM label? This will be of importance for the scientific strategy and scientific direction and for the recruitment of scientists; 6

the recruitment of a permanent scientist (open position or mobility) would help to reinforce the experimental work of the group; obtaining funding for the recruitment of post-docs seems essential, with a recommendation to increase the international diversity in the laboratory; the lab should continue to recruit master and PhD students. This is essential for the continuity of the group; the lab should continue its interactions with industrial partners but encourage team leaders to apply for national, European and international institutions academic research grants; the lab should ensure a good scientific and administrative communication between the Rouen and Caen groups; the lab should continue, and reinforce, internal scientific communication in English, essential for the international competitiveness. 7